ONCOlogic patient profiling and personalized treatment through SMART bedside diagnostics
One of 10,000+ projects Taiyo tracks in Italy.
Source: EU Funding & Tenders Portal
ONCOSMART is the first In-Vitro Diagnostic (IVD) system that determines the effectiveness of anticancer drugs for a specific patient, testing live cell response to one or multiple cancer drugs. ONCOSMART analyses bone marrow or blood samples from a specific cancer patient, providing the results within 24-48 hours. This “functional profiling” approach has shown superior performance in non-automated
- Status
- Closed
- Sector
- Power Generation (CCGT)
- Location
- Italy
- Updated
- 22 Jul 2026
- Source
- EU Funding & Tenders Portal
ConstructChat
Ask ConstructChat about ONCOlogic patient profiling and personalized treatment through SMART bedside diagnostics
Pick a question to edit it, or write your own.
First answer free · no account
Project Information FAQ
Project Information
Participants
| Not available for this record. |
Status
Original status | ended |
Taiyo status | Closed |
Taiyo last update | 2026-07-22 |
Contact
| Not available for this record. |
Description
Description | ONCOSMART is the first In-Vitro Diagnostic (IVD) system that determines the effectiveness of anticancer drugs for a specific patient, testing live cell response to one or multiple cancer drugs. ONCOSMART analyses bone marrow or blood samples from a specific cancer patient, providing the results within 24-48 hours. This “functional profiling” approach has shown superior performance in non-automated systems to current molecular/genomic methods in predicting individual patient’s response to anticancer treatments. ONCOSMART is a fully-automated and standardised functional profiling platform that is made available to doctors and researchers to identify the most suitable cancer therapy for individual patients and also aid patient selection in clinical trials. The innovative platform analyses the interactions between anticancer drugs and live tumor cells contained in 2 mL of blood or bone marrow samples. Cellply has freedom to operate and protected ONCOSMART with 2 patent families issued in EU, US and China, 1 issued in EU, 1 pending PCT application, 2 pending Italian applications. Additional value is captured by 4 patent applications to be submitted in 2018-2019. ONCOSMART can test anticancer drugs including targeted, chemo and immunotherapies alone or in combination. The test results guide the selection of: 1) the appropriate therapy for a specific patient; 2) cancer patients for specific clinical studies; 3) cancer patients for novel therapies in clinical development. The platform has been fully-engineered and tested on leukemia patients (AML), proving its predictive power, and is extended to other hematologic and solid tumors in future developments. Within this project, CellPly has the goal to industrialise the platform, validate its analytical and clinical performance and support the first commercialisation activities releasing the platform for research first, then for clinical use. |
Location
Country | Italy |
Source
Source | EU Funding & Tenders Portal |
URL |
More Details
Record type | Project |
Sector | Power Generation (CCGT) |
Article published date | 2026-02-01 |
Research
Free account
View all details
You are reading the public part. A free account opens the rest:
- Every detail on this project
- News and media coverage
- Technical research
Free account · no card · lands you back on this project
More Power Generation (CCGT) projects in Italy
- Torre Santa Susanna Solar Park
- ISAB Energy IGCC Plant
- Fiume Santo Power Station Thermoelectric Power Plant Italy
- Italiana Energia Servizi (IES) Mantua Refinery
- Algeria Sardinia Italy Gas Pipeline (Galsi)
- Milazzo Refinery and Liquid Petroleum Gas (LPG) Storage Plant, Italy
- North Adriatic LNG Terminal
- Cambrex Profarmaco, Paullo
